Investing.com — Whereas the principle story this week was the Federal Reserve’s extra cautious path for fee cuts subsequent 12 months, there have been loads of particular person shares and sector tales that resulted in volatility for some huge names. Listed here are Investing.com’s shares of the week: Micron Expertise (NASDAQ:), Novo Nordisk (NYSE:), MicroStrategy and Coinbase (NASDAQ:).
Micron Expertise
Micron Expertise shares tumbled greater than 16% Thursday after the corporate reported its newest quarterly earnings, with its outlook disappointing traders.
Whereas its Q1 EPS of $1.79 was $0.06 higher than the analyst estimate of $1.73 and income for the quarter got here in at $8.71 billion, above the consensus estimate of $8.68 billion, Micron forecast quarterly income and revenue beneath Wall Avenue estimates after the shut on Wednesday.
For Q2 2025, Micron sees its EPS between $1.33 and $1.53, beneath the consensus of $1.97. In the meantime, income for the quarter is predicted to be between $7.7 billion and $8.1 billion, decrease than the consensus estimate of $8.97 billion.
Following the earnings launch, JPMorgan lowered its goal for the inventory to $145 from $180, telling traders that “regardless of the near-term weak spot, we proceed to imagine the down-cycle in reminiscence might be short-lived.”
The financial institution expects market circumstances to enhance within the latter a part of 2025 as “modern DRAM provide stays tight and robust AI server demand continues to drive progress in HBM/DDR5.”
Novo Nordisk
It was a nasty day on Friday for Novo Nordisk shares with the inventory (on the time of writing) down 17.4% on the day.
The decline comes after the outcomes from its part 3 trial of CagriSema, its next-generation weight problems drug, disillusioned traders.
The corporate’s REDEFINE 1 trial confirmed that folks handled with CagriSema, a mixture of cagrilintide and semaglutide, achieved a weight lack of 22.7% after 68 weeks.
Nonetheless, whereas that was statistically important, it fell wanting the goal of 25%.
Following the information, rival Eli Lilly’s shares jumped.
Reacting to the outcomes, analysts at Wolfe Analysis mentioned:…
..